Table 1. Study-Wide Significant (P ≤ 2.37 × 10⁻⁷) Associations With Individual Variants in the APOE ε4⁻ Group.

Chr	Positiona	rsID	EA	Gene	GnomAD MAF (%)	Discovery					Replicationb		Discovery + Replicationb
						MAC	MAF (%)	OR (95% CI)b	P Valuec	P Valueb	OR (95% CI)	P Value	OR (95% CI)	P Value
6	41,129,252	rs75932628d	T	TREM2	0.2	68	0.50	4.85 (2.74-8.60)	2.12 × 10−9	4.59 × 10−8	2.40 (1.20-4.81)	.01	3.66 (2.36-5.68)	6.84 × 10−9
7	154,988,675	rs536940594e	A	AC099552	0	10	0.10	88.0 (9.08-852.0)	2.22 × 10−7	9.47 × 10−5	NA	NA	NA	NA
8	145,138,063	rs138412600e	A	GPAA1	2	239	2.00	2.13 (1.59-2.87)	2.70 × 10−7	3.91 × 10−7	1.47 (1.08-1.98)	.01	1.78 (1.44-2.2)	7.81 × 10−8
17	44,076,665	rs62063857d	A	MAPT	18.8	2063	16.33	1.25 (1.14-1.37)	1.83 × 10−6	4.23 × 10−6	1.12 (1.04-1.2)	2.03 × 10−3	1.17 (1.1-1.23)	1.59 × 10−7
17	448,28,931	rs199533d	A	NSF	17.8	2983	20.35	0.82 (0.76-0.89)	3.97 × 10−6	4.28 × 10−6	0.9 (0.83-0.96)	3.38 × 10−3	0.86 (0.82-0.91)	1.66 × 10−7

Abbreviations: AD, Alzheimer disease; Chr, chromosome; EA, effect allele; GnomAD, Genome Aggregation Database; MAC, minor allele count; MAF, minor allele frequency; NA, not available; OR, odds ratio; rsID, rs number.

^aPosition based on genome build GRCh37.

^bOdds ratios, 95% CIs, and P values are based on generalized linear model.

^cP value for score test.

^dAll statistics and estimates based on model 1, which adjusted only for principal components.

^eAll statistics and estimates based on model 2, which adjusted for age, sex, and principal components.